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Abstract
Background Levetiracetam, a second-generation anti-
epileptic drug (AED) with a good efficacy and safety
profile, is licensed as monotherapy for adults and children
older than 16 years with focal seizures with or without
secondary generalization. However, it is increasingly being
used off-label in younger children.
Objectives We critically reviewed the available evidence
and discuss the present status of levetiracetam mono-
therapy in children 0–16 years old.
Data Sources We systematically searched the literature
using PubMed, Web of Science and Embase up to August
2014 for articles on levetiracetam monotherapy in children.
Keywords were levetiracetam, monotherapy and child*.
The titles and abstracts of 532 articles were evaluated by
AW, of which 480 were excluded. The full texts of the
other 52 articles were assessed for relevance.
Results We covered one review, one opinion statement
and 32 studies in this review, including four randomized
controlled trials, ten open-label prospective studies, eight
retrospective studies, and ten case reports. The formal
evidence for levetiracetam monotherapy in children is
minimal: it is potentially efficacious or effective as initial
monotherapy in children with benign epilepsy with cen-
trotemporal spikes. In all of the published studies, however,
efficacy and tolerability of levetiracetam seemed to be
good and comparable to other AEDs.
Conclusion The data of 32 studies on levetiracetam
monotherapy in children were insufficient to confirm that
levetiracetam is effective as initial monotherapy for dif-
ferent types of seizures and/or epilepsy syndromes. There
is still an urgent need for well designed trials to justify the
widespread use of levetiracetam monotherapy in children
of all ages.
Key Points
Efficacy and tolerability of levetiracetam
monotherapy in children, even in very young
children, seems to be good.
Levetiracetam monotherapy in children remains off-
label because 32 studies have yielded insufficient
formal evidence for its use.
1 Introduction
Levetiracetam is a second-generation anti-epileptic drug
(AED) that has been on the market since 1999 in Europe as
add-on therapy for adolescents from the age of 16 years
with focal epilepsy.
Levetiracetam, (S)-a-ethyl-2-oxo-1-pyrrolidine ac-
etamide, is the (S)-enantiomer of the ethyl analogue of
piracetam and shares its chemical structure with numerous
nootropic drugs [1, 2]. The mechanism of action differs
structurally and functionally from other currently available
AEDs as it binds to the synaptic vesicle protein 2A
(SV2A). The presence of SV2A in the presynaptic termi-
nals suggests that its anti-epileptic function might be based
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on it affecting presynaptic events that regulate synaptic
vesicle release [3]. Although its precise mechanism of
action is not known, Nowack et al. [4] suggested that
levetiracetam might modulate SV2 protein interactions. As
a consequence, normal levels of SV2 and synaptotagmin (a
SV2-binding protein) at the synapse are maintained, which
may reduce seizures. It also plays a role in Ca2? home-
ostasis by inhibiting ryanodine and IP3 receptor-dependent
Ca2? release from endoplasmic reticulum and by inhibiting
Ca2? entry through blocking of the L-type Ca2? channels
in hippocampal neurons [5].
Levetiracetam is almost completely absorbed after oral
administration and its bioavailability is close to 100 %; it is
unaffected by food [6]. Peak plasma concentrations occur
in 1 h and steady state concentrations are achieved in
2 days if levetiracetam is taken twice daily. Pharmacoki-
netics is linear, dose proportional and time independent [6].
The distribution is close to the volume of intracellular and
extracellular water and levetiracetam remains almost
unattached to proteins [7]. Levetiracetam is minimally
metabolized and, after 24 h, 27 % is excreted as inactive
metabolites [8]. The metabolism of levetiracetam does not
involve the hepatic cytochrome P450 (CYP) system, nor
does it inhibit or induce hepatic enzymes [6]. The major
elimination route for levetiracetam is renal; 66 % as an
unchanged drug [9]. Dose adjustments are only recom-
mended in patients with moderate to severe renal impair-
ment or severe hepatic impairment with concomitant renal
insufficiency. The body clearance of levetiracetam in
children is 30–40 % higher compared with adults and it is
therefore recommended that children have a daily main-
tenance dose on a weight normalized level (20–60 mg/
kg/day) divided over two doses; this is equivalent to
130–140 % of the usual daily adult maintenance dosage
(1000–3000 mg/day) [10]. Levetiracetam has no clinically
meaningful drug–drug interactions with other AEDs, or
non-AEDs such as oral contraceptives, warfarin and
digoxin. Thus, because of its unique chemical structure,
specific mode of action and pharmacokinetic profile,
levetiracetam has become one of the most widely used
second-generation AEDs for both adults and children.
Levetiracetam was licensed as add-on therapy in chil-
dren in 2005. Nowadays, levetiracetam is registered in
Europe and the US as add-on therapy for focal onset sei-
zures with or without secondary generalization in patients
from 1 month of age, as add-on therapy for myoclonic
seizures in patients from 12 years of age with juvenile
myoclonic epilepsy, and as add-on therapy for primary
generalized tonic-clonic seizures in patients with idiopathic
generalized epilepsy (in Europe from 12 years of age; in
the US from 6 years of age).
It was not until 2006 that it was licensed as mono-
therapy, but only in Europe, for adults and children from
16 years of age with focal onset seizures with or without
secondary generalization. Off-label use of levetiracetam as
monotherapy in younger children has increased consider-
ably over the last decade due to its efficacy in both focal
and generalized seizures, its good safety profile, favourable
pharmacokinetic properties and its availability in an in-
travenous form for the acute setting [11–18].
Here, we review the available evidence for the use of
levetiracetam monotherapy in children in the literature,
including data from randomized controlled trials. We also
discuss the present status of levetiracetam and make some
recommendations for future research.
2 Methods
For this review, a literature search was performed by AW
using PubMed (Medline), Web of Science and Embase
(until August 2014) for papers on levetiracetam mono-
therapy in children (\18 years of age). There are no
Cochrane Reviews on levetiracetam monotherapy. The
following search terms were used: levetiracetam AND
monotherapy AND child*. Only papers written in English,
Dutch, French, or German were included. Articles were
screened by AW and, in case of any dispute, discussed with
PMCC. If a study included both children and adults, it was
reviewed only if the results of efficacy were reported
separately for children. We also searched the reference lists
of these publications for more articles relevant to the topic.
Abstracts of congress proceedings were not included. Data
extraction from the articles was done independently by AW
in Word and monitored by PMCC. We critically evaluated
the study designs and whether there was any risk of bias in
the individual studies.
3 Overview of Published Articles
The systematic literature search yielded 690 articles. After
removing duplicates, the titles and abstracts of 532 articles
were evaluated by AW; 480 were excluded (Fig. 1). The
full texts of the other 52 articles were assessed for relevance
and 34 articles were included in this systematic review: four
randomized controlled trials (RCTs), ten open-label
prospective studies, eight retrospective studies, ten case
reports, a review, and an opinion statement [12, 19–51].
3.1 Review, Opinion Statement and Case Reports
One review and one opinion statement argued that leve-
tiracetam monotherapy should be the drug of choice in
patients with juvenile myoclonic epilepsy, based on evi-
dence from trials, especially if valproic acid is contra-
372 A. Weijenberg et al.
indicated; for example, in women of child-bearing age [50,
51].
Ten case reports have been published on the use of
levetiracetam monotherapy in children, including neonates,
with a wide variety of seizure types, epilepsy syndromes,
dosages and ages (Table 1) [40–49]. Dosages of leve-
tiracetam were given in mg/kg/day or mg/day or not
documented. All children became seizure-free, but the
duration of follow-up was not given in three case reports
(Table 1). The case reports suggested a high efficacy of
treatment with levetiracetam monotherapy, and adverse
events were infrequent or they were not reported.
3.2 Retrospective Studies
Eight retrospective studies on levetiracetam monotherapy
in children have been published, the first in 2004 (Table 2)
[32–39]. Most of them included patients with focal and/or
generalized epilepsy. Levetiracetam dosage in these studies
ranged from 10 to 108 mg/kg/day, but was mostly in the
20–40 mg/kg/day range. The mean duration of follow-up
ranged from 3 to 27 months; four studies had a follow-up
of more than 1 year [34, 35, 37, 38]. Three studies
compared efficacy and tolerability of levetiracetam with
carbamazepine [35], with oxcarbazepine or valproic acid
[36], and with valproic acid [38].
In all but one of the eight studies, levetiracetam efficacy
was considered to be good, and seizure freedom was
achieved in more than 60 % of patients in most studies,
including those on children who had been using another
AED prior to levetiracetam monotherapy (Table 2). Tol-
erability was good in all studies, with behavioural and
cognitive changes being the most common adverse events;
the discontinuation rate due to adverse events was low
(0–12 %). In one study, the retention rate was not sig-
nificantly different between the two groups (levetiracetam
vs oxcarbazepine and levetiracetam vs valproic acid),
although levetiracetam monotherapy failed more often due
to lack of efficacy in both groups [36].
3.3 Prospective Open-Label Studies
Lagae et al. [12] were the first to report a prospective trial
on levetiracetam monotherapy in children. Since then, nine
more open-label prospective studies have been published
that included children, and sometimes even neonates, with
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Fig. 1 PRISMA flow diagram. LEV levetiracetam
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different but overall relatively benign seizure types and/or
epilepsy syndromes (Table 3) [23–31]. In three studies,
levetiracetam was given in mg/day, without considering
body weight, with dosages ranging from 1000 to
3000 mg/day [23, 24, 27]. In seven studies, dosages were
based on bodyweight, starting with 10 mg/kg/day, with
increasing dosage until seizure freedom was reached, with
a maximum of 70 mg/kg/day (Table 3) [12, 25, 26, 28–31].
In a pilot study by Kossoff et al. [26], children were
switched from carbamazepine or oxcarbazepine mono-
therapy to levetiracetam monotherapy. The baseline AED
was tapered off over 2 weeks. Verrotti et al. [24] reported
on 21 children who received levetiracetam monotherapy:
12 of them were converted from monotherapy with val-
proic acid, carbamazepine, oxcarbazepine, or lamotrigine
to levetiracetam monotherapy. However, follow-up was
more than 1 year in only half of these trials; this is regarded
as the minimum duration to draw any conclusions about
long-term efficacy, adverse events and tolerability of AED
treatment [52, 53].
In most studies, efficacy of levetiracetam monotherapy
was reported to be good, with a high percentage of children
becoming seizure free (20–100 %) or having more than
50 % seizure reduction (62–100 %). In one study, the re-
sponse was significantly better in the children who were
AED-naive before initiating treatment with levetiracetam
[24]. Some studies used extra outcome parameters other
than efficacy, such as quality of life [12], electro-en-
cephalography (EEG) findings and language function [26].
Lagae et al. [12] studied ten children and observed in-
creased alertness in three and a positive effect on behaviour
in one. Furthermore, median overall quality of life was
higher in children on levetiracetam monotherapy than in
children with add-on levetiracetam [12]. Kossoff et al. [26]
evaluated EEG findings and language function in six
children with benign epilepsy with centrotemporal spikes
(BECTS), and they also looked for additional evidence of
impaired auditory comprehension and verbal memory.
After 6 months of treatment, the parents of all children
reported subjective improvements, which were confirmed
in most children by objective testing. The EEG had nor-
malized in only three children.
Six trials reported the occurrence of adverse events,
most commonly irritability and somnolence [12, 24, 26, 28,
29, 31]. In three, all adverse events were transient [24, 28,
29] and in two, none of the children discontinued leve-
tiracetam because of adverse events [12, 26]. In a large
study of 37 children on levetiracetam monotherapy and 83
children on levetiracetam add-on treatment, a relatively
high percentage reported adverse events (47.5 %) and four
of them even had to discontinue levetiracetam [31]. Results
for the group treated with monotherapy were, however, not
given separately.
3.4 Randomized Controlled Trials
Four RCTs have been published: two open-label parallel
group trials and two double-blind trials (Table 4) [19–22].
Most trials only included children with a well described
epilepsy syndrome such as BECTS [19, 22] or absence
epilepsy (childhood absence epilepsy [CAE], juvenile ab-
sence epilepsy [JAE]) [20]. The age at enrolment varied
between 3 and 17 years. The maximum dosage of leve-
tiracetam was 2000 mg/day in 12- to 17-year-old children
[21] or 30 mg/kg/day [19, 20, 22]. One trial was placebo-
controlled [20] and, for obvious ethical reasons [54], the
duration of the double-blind period was only 2 weeks,
which is much shorter than the duration of the other trials
(24–78 weeks).
The equivalence open-label trial of Coppola et al. [19]
compared levetiracetam with oxcarbazepine in children
with BECTS and they observed no significant difference in
the percentage being seizure free at 18 months (Table 4).
In another trial, in children with absence epilepsy, Fattore
et al. [20] showed no significant difference in seizure
freedom between levetiracetam and placebo. After the
2-week double-blind period, the trial continued as an open-
label trial and almost all children receiving the placebo
were switched to levetiracetam. During long-term follow-
up, 32 % (12/38) of the children initially on levetiracetam
continued with levetiracetam and were seizure-free for at
least 267 days; 63 % (24/38) discontinued levetiracetam
because of inefficacy at a later stage. After 1 year, 17
children (29 %) were still seizure-free on levetiracetam
(initially on levetiracetam or placebo therapy). Rosenow
et al. [21] included patients aged C12 years with newly
diagnosed focal or generalized epilepsy. If patients were
already using an AED, this was tapered off during the first
3 weeks of the study period. A post-hoc subgroup analysis
was performed for 33 patients aged 12–17 years. Seizure
freedom after 6 weeks of treatment was compared between
levetiracetam and lamotrigine, although patients on lam-
otrigine were still in their titration period and the dosage of
lamotrigine also increased after this time-point. Efficacy
and tolerability of levetiracetam and lamotrigine did not
differ significantly for the group aged 12–17 years. Qual-
ity-of-life scores (QOLIE-10) at the beginning and end of
treatment (26 weeks) were similar in both treatment
groups; a subgroup analysis for children aged 12–17 was
not presented. In the non-inferiority trial of Borggraefe
et al. [22], levetiracetam was compared with sulthiame in
children with BECTS. Their primary endpoint was treat-
ment failure, defined by seizure recurrence during the ob-
servation period. This was not significantly different
between treatments (Table 4). However, the retention rate
was significantly higher in the sulthiame group than in the
levetiracetam group (p = 0.03).
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The most commonly reported adverse events were
somnolence and irritability or behavioural problems. Sig-
nificant differences with respect to adverse events were not
observed between the treatments reported. However, none
of the trials used a standardized questionnaire to investigate
the occurrence of adverse events.
4 Discussion
In this review, 32 studies on levetiracetam monotherapy in
children are described. In all of them, efficacy and tolerability
of levetiracetam monotherapy seems to be good and com-
parable or even favourable to other AEDs. Nonetheless, we
must recognize that it has only been licensed for monotherapy
in children older than 16 years in Europe.
4.1 Current Evidence for Efficacy
The most commonly used primary endpoint for efficacy
was seizure freedom and/or percentage of seizure reduction
(30 of 32 studies). The case reports suggested a very high
efficacy of treatment with levetiracetam monotherapy.
Publication bias may, however, have led to an unrealistic
positive view of its efficacy. The percentage of children
becoming seizure-free in both retrospective and prospec-
tive studies was 61–100 %. Only 20–46 % of cases became
seizure-free in three prospective open-label studies that
included children with all seizure types or even West
syndrome [12, 25, 31]. Efficacy of levetiracetam does not
seem to be related to age at enrolment, dosage or seizure
type and/or epilepsy syndrome (Tables 1, 2, 3, 4). Since
most studies included children with overall relatively be-
nign seizure types and/or syndromes, its efficacy might be
overestimated. In summary, the efficacy of levetiracetam
monotherapy in children seems good and comparable to
other AEDs, but the level of evidence is limited and not
available for all seizure types and/or epilepsy syndromes.
4.2 Current Knowledge on Tolerability
The range of children with reported adverse events varied
between 0 and 47.5 %. The percentage of children who had
to stop levetiracetam treatment due to adverse events was
0–12 % in most studies, although in the trial of Borggraefe
et al. [22], 23.8 % of the children discontinued levetirac-
etam because of adverse events. The most frequently re-
ported adverse events were behavioural and/or cognitive
changes (i.e. irritability, mood disturbances or somno-
lence), but these complaints were mostly transient. This is
in line with the most commonly reported adverse events for
levetiracetam [55]. In children with pre-existing be-
havioural problems, the problems could be exacerbated
during levetiracetam therapy [56]. In some, but not all, of
the prospective studies, pre-existing behavioural and/or
cognitive problems were exclusion criteria [24, 26–29]. In
two RCTs, children with a mental deficit or intellectual
disability were excluded [19, 20]. The other two RCTs did
not mention any exclusion criteria for behavioural and/or
cognitive problems [21, 22]. Because children with
epilepsy may develop cognitive and/or behavioural prob-
lems due to both the epilepsy itself and the treatment with
AEDs, it is very important to evaluate the exact role of
treatment on these problems as well [54, 57]. According to
Cross et al. [58], effective management requires treatment
within the context of the overall health status and quality of
life of the treated child. Two trials investigated quality of
life, and this was unchanged or positively influenced by the
use of levetiracetam monotherapy [12, 21].
In summary, the tolerability of levetiracetam seems to
be good, with only a few adverse events that are mostly
transient, even in very young children and in dosages up to
70 mg/kg/day.
4.3 Evaluation of Study Design and Methodology
According to the International League Against Epilepsy
(ILAE), the best evidence for the use of levetiracetam
monotherapy in children up to March 31, 2012 reached
level D for children with BECTS, based on the study by
Coppola et al. [19, 53]. Level D means there is one class III
double-blind or open-label study, or one or more class IV
clinical studies or data from expert committee reports or
opinions from experienced clinicians [53]. Since 2012, two
more RCTs on levetiracetam monotherapy have been
published, both with a class III rating [21, 22]. Because of
the inconclusive trial results of Borggraefe et al. [22], the
level of evidence for levetiracetam monotherapy in BECTS
did not reach level C, while the trial results of Rosenow
et al. [21] could not contribute to the level of evidence for
levetiracetam monotherapy in focal and generalized
epilepsy because of their study design.
Prospective studies may also contribute to the level of
evidence. However, eight of the ten prospective studies did
not perform a formal statistical evaluation, and only one of
the other two studies found a significant decrease in seizure
frequency in a subgroup analysis [12, 23–31]. Although
these ten studies did not contribute to the level of evidence
for levetiracetam monotherapy in children, the percentage
of children becoming seizure-free after the start of leve-
tiracetam is promising, although there may well be some
publication bias.
The reasons for the small number of prospective trials
performed in children are pharmaceutical companies’ lack
of interest in such a small market when the patent has
expired, and the difficulties in recruiting patients, partially
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due to ethical and legal aspects [59]. Moreover, in the past,
separate drug trials in children were not required. As a
consequence, levetiracetam is often prescribed off-label for
children based on the results of trials in adults. Children,
however, have a different developmental physiology, dis-
ease pathophysiology, pharmacokinetics and/or pharma-
codynamics, resulting in treatment responses that are
unpredictably different from those in adults [60, 61]. There
is therefore an urgent need for clinical trials in children,
because\50 % of medicines used in children have been
properly studied in this age group [62]. For example, anti-
epileptic drugs that have been registered as add-on therapy
in children and/or as monotherapy in adults should also be
studied as monotherapy in children; this is already obli-
gatory for drugs now being developed.
The ILAE has described an ideal design for clinical trials
in children [53]. This includes a randomized double-blind
design, with adequate sample size calculations leading to a
large enough study population to show non-inferiority with
a B20 % relative difference between treatment arms, based
on 80 % power in a non-inferiority analysis versus an ac-
ceptable comparator; with retention rate or seizure freedom
as the primary endpoint after a minimum of 48 weeks of
treatment, and an appropriate statistical analysis. Of the four
RCTs on levetiracetam in children, only two were double-
blind studies [19, 22]. Remarkably, these two studies
compared levetiracetam with oxcarbazepine or sulthiame in
children with BECTS, whereas the level of evidence for the
efficacy of both oxcarbazepine and sulthiame is low [19, 22,
53]. Carbamazepine and valproic acid would have been a
more obvious choice for comparison of efficacy [53]. Fur-
thermore, the follow-up duration in the Borggraefe et al.
[22] study was only 24 weeks.
In our opinion, one of the best ways to measure efficacy,
side effects and tolerability is by using retention rate, be-
cause this endpoint combines all these parameters [52].
Retention rates in the prospective open-label studies and
RCTs ranged from 57.1 to 100 % (Tables 3, 4).
One limitation of our review is that we did not include
conference papers and that the literature search and
screening of articles was done by only one person. Another
is that we did not perform a meta-analysis. This was not
possible due to the heterogeneity of the population with
varying epilepsy syndromes and seizure types, the variation
in study designs and the different AEDs used for
comparison.
5 Conclusion and Recommendations
The formal evidence for the use of levetiracetam mono-
therapy in children remains quite scarce: it is potentially
efficacious or effective as initial monotherapy in children
with BECTS. Because of the study designs and the limited
number of trials, there is insufficient data available to
confirm that levetiracetam is effective as initial mono-
therapy in children for different types of seizures and/or
epilepsy syndromes, other than BECTS.
More importantly, however, in the studies we evaluated,
the efficacy of levetiracetam monotherapy in children
seems at least equally comparable to other AEDs. The
spectrum of reported adverse events is favourable, and
levetiracetam does not have a negative impact on cognition
[63]. Together with its availability in an intravenous form,
unique chemical structure, novel mode of action and phar-
macokinetic profile, levetiracetam may become one of the
most important AEDs in treating children with epilepsy.
To formally justify the widespread use of levetiracetam
monotherapy in children of all ages, we need more well
conducted, double-blind RCTs to evaluate the efficacy,
side effects and tolerability of levetiracetam monotherapy
in children.
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